Spanish Lung Cancer Group
Published: 3 Dec 2008
Views: 15540
Prof. Rafael Rosel
Benefits of customising erlotinib therapy for NSCLC.
- Categories:
- Lung & pleura
Related Videos
Lung cancer updates from ASCO 2020
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
17 Jul 2020
Why the ADAURA study is a big step forward for NSCLC
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
17 Jul 2020
Background of the KEYNOTE-158 trial for pembrolizumab in advanced mesothelioma
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
15 Jul 2020
Novel immunotherapy approaches for small cell lung cancer
Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York City, USA
15 Jul 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
Preclinical models for small-cell lung cancer
Prof Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands
18 Jun 2020
CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
17 Jun 2020
High-dose twice daily thoracic radiotherapy in limited disease small-cell lung c...
Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway
15 Jun 2020
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung can...
Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA
12 Jun 2020
